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As the principal coreceptors of human immunodeﬁciency virus
type 1 (HIV-1) infection, chemokine receptors CCR5 and CXCR4
cooperate with the CD4 receptor to mediate virus entry (Berger et al.,
1999). HIV-1 coreceptor tropism is deﬁned as the ability of a virus to
use CCR5 only (R5), CXCR4 only (X4), or both of these coreceptors
(dual). R5 virus populations represent the majority of HIV-1
infections, followed by dual/mixed (R5 plus dual and/or X4) virus
populations; X4 virus populations are relatively rare. R5 variants
predominate during acute and early infection and generally persist
throughout the entire course of HIV-1 infection (Berger et al., 1999).
In contrast, CXCR4-using variants (dual and, to a lesser extent, X4
viruses) are detected infrequently in recent infections (Eshleman et
al., 2007; Huang et al., 2009; Markowitz et al., 2005; Masquelier et al.,
2007), but gradually increase in prevalence as chronic infection
ensues (Berger et al., 1999; Connor et al., 1997; Melby et al., 2006;Schuitemaker et al., 1992;Wilkin et al., 2007). Generally, CXCR4-using
variants are found in approximately 20% of antiretroviral (ARV)
treatment-naive individuals, characterized by higher CD4+ T-cell
counts (Brumme et al., 2005; Moyle et al., 2005), and approximately
50% of highly treatment-experienced patients, characterized by low
CD4+ T-cell counts (Coakley et al., 2006; Demarest et al., 2004; Hunt
et al., 2006; Melby et al., 2006; Wilkin et al., 2007). In the absence of
ARV treatment, the presence of CXCR4-using viruses is strongly
associated with faster depletion of CD4+ T cells and accelerated
disease progression (Daar et al., 2007; Koot et al., 1993; Richman and
Bozzette, 1994; Schuitemaker et al., 1992; Shepherd et al., 2008;
Tersmette et al., 1989). Whether these associations are causal or
consequential has not been ﬁrmly established and is the subject of
ongoing debate.
More recently, the development of CCR5 antagonists as new
therapeutic agents has drawn further attention to HIV-1 coreceptor
tropism. The CCR5 antagonist maraviroc (Pﬁzer) is approved for the
treatment of HIV-1 infection in patients that have failed conventional
treatment regimens comprised of nucleoside, non-nucleoside, and/or
protease inhibitors (Gulick et al., 2008), and more recently in the
treatment-naive setting (Cooper et al., 2010). Several additional
therapeutic candidates have advanced to late stage clinical evalua-
tions, including the small molecule CCR5 antagonists vicriviroc
(Gulick et al., 2007; Su et al., 2009; Suleiman et al., 2010) and
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and Opportunistic Infections, Boston, MA, Feb. 3–6, 2008), as well as
the CCR5 monoclonal antibody Pro-140 (Jacobson et al., 17th
Conference on Retroviruses and Opportunistic Infections, San Fran-
cisco, CA, Feb. 16–19, 2010). In each case, these CCR5 inhibitors
effectively suppress the replication of R5 virus populations, but not
dual/mixed or X4 virus populations (Lewis et al., 2007; Saag et al.,
2009; Tsibris et al., 2009; Westby et al., 2006). Although initial
attempts to develop therapeutic agents that block CXCR4-mediated
entry have met with less success (Hendrix et al., 2004; Moyle et al.,
2009), several new candidates have recently entered early-stage
clinical evaluations (Jenkinson et al., 2010; Murakami et al., 2009).
Since CXCR4 inhibitors effectively suppress the replication of X4 virus
populations, but not R5 or dual/mixed virus populations (Fransen et
al., 2008; Hendrix et al., 2004), their use in the clinic may be linked to
co-administration with CCR5 inhibitors.Table 1
Comparison of coreceptor tropism of patient virus populations containing different amin
genotype (PSSM and 11KR/25KR).
a
The 11R and 25K/R substitutions and the absence of the potential N-linked glycosylatio
at these positions).
b Infectivity was measured as luciferase activity (relative light units, RLU) using the Troﬁle ass
The ratios of CXCR4 RLU to CCR5 RLU are indicated for DM viruses. ND: CXCR4/CCR5 ratios we
either CXCR4 or CCR5 cells.
c Coreceptor tropism predictions by genotypic algorithms that do not match the phenotyNumerous studies have ﬁrmly established the third variable region
(V3) of the HIV-1 envelope glycoprotein (Env) as a primary
determinant of coreceptor tropism (Cocchi et al., 1996; Deng et al.,
1996; Hoffman and Doms, 1999; Hung et al., 1999; Hwang et al., 1991;
O'Brien et al., 1990; Shioda et al., 1991; Speck et al., 1997; Trkola et al.,
1996; Trujillo et al., 1996;Westervelt et al., 1992;Wu et al., 1996). The
substitution of as few as one or two amino acids in the V3 region of R5
viruses can confer CXCR4 use (Chesebro et al., 1996; De Jong et al.,
1992; Mosier et al., 1999). However, more complex patterns of amino
acid substitutions in the V3 region are typically observed among the
CXCR4-using variants within patient virus populations that also
contain an R5 subpopulation for comparison (Huang et al., 2007;
Jensen et al., 2003; Lewis et al., 2007; Tsibris et al., 2009;Westby et al.,
2006). Previous studies have deﬁned speciﬁc determinants of
coreceptor tropism within the V3 region, including the acquisition
of positively charged amino acids, particularly at positions 11 and 25o acid substitutions at positions 11, 25, or 6–8 assigned by phenotype (Troﬁle) and
n site (PNGS) at positions 6–8 in V3 are shown in boldface (no mixtures were detected
ay. RLU b200 represents background levels of luciferase activity on CCR5+ or CXCR4+cells.
re not determined because luciferase activity (RLU) was at or below background levels for
pic determination by the Troﬁle assay are highlighted in gray.
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more recently, position 24 (Cardozo et al., 2007), as well as the loss of
a potential N-linked glycosylation site (PNGS) at positions 6–
8 (Pollakis et al., 2001). A recent study has demonstrated that the
ability to accurately predict CXCR4 use is CD4 independent for viruses
with a positively charged amino acid at position 11, but is CD4
dependent for viruses with positively charged amino acids at position
25, or that lack a PNGS at positions 6–8 (Low et al., 2008). Precisely
how substitutions at positions 11, 25, and 6–8 impact CXCR4 use
requires further investigation.
To advance our understanding of how HIV-1 populations broaden
or switch host range, i.e. coreceptor tropism, either as a result of host-
or drug-imposed selective pressure, we have attempted to more
clearly deﬁne the associations between speciﬁc V3 determinants for
CXCR4 use and their impact on Env mediated entry by analyzing
patient-derived viruses. The primary goal of the present study is to
speciﬁcally deﬁne the selective advantages and disadvantages of V3
mutational pathways that lead to efﬁcient CXCR4 use. In doing so, we
have examined the effect of positively charged amino acids at
positions 11 and 25, as well as the absence of a PNGS at positions
6–8 on CXCR4 use by analyzing (a) the envelope (env) sequences of
35 patient virus populations containing any one of these V3
substitutions in isolation, (b) multiple individual env clones derived
from 12 patient virus populations containing mixed amino acid
sequences at these positions, and (c) ﬁve different env sequences
containing speciﬁc V3 amino acid substitutions introduced by site-
directed mutagenesis. We found that these speciﬁc V3 substitutions
differentially inﬂuence CXCR4 mediated entry, and their effects are
highly context dependent and reliant on the presence of additional
env amino acid substitutions that serve to compensate for reductions
in env infectivity, or act cooperatively to confer efﬁcient CXCR4 use.
The degree of complexity and ﬂuidity of mutational pathways leading
to CXCR4 use that we observed is consistent with a high geneticTable 2
env clonal analysis of four patient virus populations containing mixed amino acid substitut
Subject
(subtype)
Virusesa Position
11b
V3 amino acid sequencesc
1(B/C) Population S/R
Clone (n=4) S CTRPNNNTRKSIHIGPGK-SIFATGDII
Clone (n=1) S .............M...S..F.......
Clone (n=1) S .......A.....M...S..F.......
Clone (n=2) R .I........R..T.L.RW..IT.....
2(B) Population G/R
Clone (n=1) G CIRPNNNTRKGIHIGPGRAFYTTGQVVG
Clone (n=2) G ............................
Clone (n=4) R ..........R.S.......V..E....
Clone (n=3) R .T........R.S.......V..E....
3(AE) Population S/R
Clone (n=4) S CTRPNNNTRTSITIGPGQVFYKTGDIIG
Clone (n=1) S ........................E...
Clone (n=1) S ........................E...
Clone (n=3) R ..........R......R.Y....E...
4(B) Population S/R
Clone (n=6) S CTRPNNNTRKSITMGPGRVLYTTGQIIG
Clone (n=1) R ..........R.................
Clone (n=1) R ..........R.........H.......
a Clones with identical V3 sequences and the same coreceptor tropism are grouped togethe
for reverse site directed mutagenesis.
b The 11R substitutions in V3 are shown in boldface.
c For V3 amino acid sequences, dots represent amino acids identical to the ﬁrst sequence,
and 6–8 (for PNGS) are underlined.
d The number of amino acids that differ from the most prevalent V3 sequence of R5 clon
clones, and the number of amino acid differences between clones with or without 11R is sh
e Coreceptor tropism was determined by the Troﬁle assay. Dual clones were further classiﬁ
previously (Huang et al., 2007). R5 and dual-X clones from subject 3 that shared identical V
that shared identical V3 amino acid sequences, except at position 11 (S or R), are highlight
f Infectivity wasmeasured as luciferase activity (relative light units, RLU) in the Troﬁle assa
this study. Infectivity of multiple clones with the same V3 sequence is expressed as the avebarrier and may, in part, explain why CXCR4 use typically emerges
late in the course of HIV infection, if at all.
Results
Patient-derived viruses that contain basic amino acids at V3 position 11
or 25, or that lack an N-linked glycosylation site in V3, vary in their
ability to use CXCR4 and CCR5
To better deﬁne the contributions of positively charged amino acid
substitutions and the loss of PNGS in the env V3 region to CXCR4-
mediated entry, we inspected the V3 sequences of 200 patient virus
populations that were submitted for routine coreceptor tropism
testing (Troﬁle). This initial inspection deﬁned an unambiguous
subset of 35 viruses that either contained a basic amino acid
substitution at position 11 (N=7) or 25 (N=25) or lacked a PNGS
at positions 6–8 (N=3) (Table 1). The majority of these viruses (31/
35) were subtype B (C=1, B/D=1, A/G=2). All seven of the basic
substitutions at position 11 were arginine (11R); no lysine (11K) was
observed. In contrast, basic substitutions at position 25 were equally
represented by arginine (25R, N=15) and lysine (25K, N=11). The
coreceptor tropism (R5, DM, X4) and infectivity (luciferase reporter
gene activity expressed as relative light units, RLU) of these 35 viruses
are summarized in Table 1. All seven viruses containing 11R
substitutions utilized CXCR4 efﬁciently relative to CCR5, i.e., infectivity
was comparable or higher in CXCR4+ cells than in CCR5+ cells
(median ratio of CXCR4 RLU:CCR5 RLU=4.673, range=0.720–
14.971), thus no 11R viruses were classiﬁed R5. In contrast, roughly
one third (8/25) of the 25K/R virus populations were R5 viruses. The
remaining 25K/R virus populations (17/25) were classiﬁed DM or X4
but varied (N4 log10 RLU) in their ability to utilize CXCR4 (median ratio
of CXCR4 RLU:CCR5 RLU=1.034, range=0.001–129.905). Similarly,
CXCR4 utilization varied (N4 log10 RLU) in 2/3 viruses that lacked theions at position 11 in V3.
No. of
AA
changesd
Coreceptor
tropisme
Infectivity (RLU)f
CXCR4+ cells CCR5+ cells
DM 14,188 523,551
GDIRQAHC 0 R5 83 951,905
....K.. 4 R5 63 556,160
....K... 5 R5 157 1,015,357
........ 8 Dual-X 564,997 432,732
DM 73,347 55,808
DIRQAHC 0 R5 177 69,366
....... 0 Dual-R 660 1,456,992
...K... 5 Dual-X 681,919 350,020
...K... 6 Dual-X 730,141 174,252
DM 6091 142,291
DIRKAYC 0 R5 121 603,308
...R... 2 R5 74 1,211,595
...R... 2 Dual-X 16,534 13,848
N...... 5 Dual-X 1,026,300 693,476
DM 560,500 745,641
DIRKAYC 0 Dual-X 879,283 531,108
....... 1 Dual-X 173,666 126,407
....... 2 Dual-X 29,439 40,645
r. One dual clone from subject 2 and one from subject 3 (indicated in bold) were chosen
dashes in the ﬁrst sequence indicate gaps to accommodate insertions. Positions 11, 25,
es in the same sample is indicated, except for subject 4. Subject 4 contained only dual
own.
ed as dual-X and dual-R based on efﬁcient or inefﬁcient utilization of CXCR4, as deﬁned
3 amino acid sequences are highlighted (bold and italics). Dual-X clones from subject 4
ed (bold and italics).
y. RLU b200 on CCR5+ or CXCR4+ cells was considered background luciferase activity in
rage RLU.
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range=1.083–449.225), while the remaining virus was R5.
All but one of the seven viruses containing 11R substitutions were
consistently predicted to use CXCR4 based on the V3 genotype-based
algorithms PSSM and 11/25 rule. These predictions were highly
concordant with phenotypicmeasurements of CXCR4 use (Table 1). In
contrast, genotypic predictions of CXCR4 use or CCR5 use for the
subset of viruses containing 25K/R substitutions were often discor-
dant with phenotypic measurements (11 of 25 viruses misclassiﬁed
by PSSM, 8 of 25 viruses misclassiﬁed by 11/25 rule). Similarly,
genotypic algorithms also misclassiﬁed CXCR4 use among viruses
lacking the PNGS within the V3 region (1 of 3 viruses misclassiﬁed by
PSSM, 2 of 3 viruses misclassiﬁed by 11/25 rule) (Table 1).
Among the 35 viruses evaluated, six additional amino acid
substitutions—glutamate (E), aspartate (D), glutamine (Q), glycine
(G), alanine (A), and serine (S)—were observed at position 25 (10
viruses), in addition to K and R (25 viruses). Four amino acid
substitutions—predominantly S (14/28) and G (11/28), and rarely
histidine (H, 1/28), and isoleucine (I, 1/28)—were observed at
position 11 in 28 viruses, in addition to R in seven viruses (Table 1).
These data suggest that HIV-1 can accommodate a greater diversity of
amino acid substitutions at position 25 versus position 11 in V3.
Notably, in addition to the 200 viruses surveyed in the current study,
11K was also not observed upon surveying 1,148 env sequences of
patient viruses compiled by our laboratory (Stawiski et al., unpub-
lished observations).
11R substitutions in V3 strongly promote but are not essential for the
efﬁcient use of CXCR4
To further examine the contribution of the 11R substitution to
CXCR4 usage, we next characterized the coreceptor tropism and V3Table 3
env clonal analysis of ﬁve patient virus populations containing mixed amino acid substituti
Subject
(subtype)
Virusesa Position
25b
V3 amino acid sequencesc
5(B) Population E/K
Clone (n=4) E CTRPNNNTRKSIHIAPGRAFYATGEIIG
Clone (n=1) E .........................V..
Clone (n=1) D ........................D...
Clone (n=2) K ........................K...
6(B) Population G/R
Clone (n=3) G CTRPSNNTRKSISIGPGRALYTTGGIIG
Clone (n=8) R ............P...........R...
7(C) Population E/K
Clone (n=3) E CVRPNNNTRKGIGIGPGQTFYARNEIIG
Clone (n=1) E .I....................-.....
Clone (n=4) K .A...............R......K...
8(B) Population D/K
Clone (n=5) D CTRPNNNTRKGIHIGPGGSFFATGDIIG
Clone (n=3) K ......YST...V.R.....Y...K...
9(B) Population E/R
Clone (n=4) E CTRPNNNTRRSIHIQPGRAFYATGEIIG
Clone (n=1) E ............................
Clone (n=1) R .S.......KA.P.H..GT...RDR...
Clone (n=1) R .S....YS.KA.P.H..GT...RDR...
Clone (n=1) R .S....YSTKA.P.H..GT...RDR...
a Clones with identical V3 sequences and the same coreceptor tropism are grouped toge
b The 25K/R substitutions in V3 are shown in boldface.
c For V3 amino acid sequences, dots represent amino acids identical to the ﬁrst sequence, d
underlined.
d The number of amino acids that differ from the most prevalent V3 sequence of R5 clon
e Coreceptor tropism was determined by the Troﬁle assay. Dual clones were further classiﬁ
previously (Huang et al., 2007).
f Infectivity wasmeasured as luciferase activity (relative light units, RLU) in the Troﬁle assa
this study. Infectivity of multiple clones with the same V3 sequence is expressed as the avesequences of multiple envmolecular clones derived from four patient
virus populations that had mixed amino acid sequences at position 11
(env subtype B=2, B/C=1, AE=1) (Table 2). Three virus populations
(subjects 1–3) were comprised of mixtures of R5 and dual variants,
while the remaining virus population (subject 4) was comprised
solely of dual variants. In all four subjects, 11R variants were mixed
with either 11S (subjects 1, 2, and 4) or 11 G (subject 3) variants
(consistent with the position 11 substitutions that we observed for
the 35 viruses listed Table 1). Based upon infectivity, every 11R env
clone isolated from all four subjects utilized CXCR4 efﬁciently relative
to CCR5. This phenotype of 11R env clones is consistent with the 11R
virus populations described in Table 1 and with our previous
description of a dual-X virus subclassiﬁcation (Huang et al., 2007).
It is important to note that we also identiﬁed dual-X variants that
lacked 11R substitutions in two of the four patient viruses evaluated
(Table 2). In subject 3, we identiﬁed one dual-X variant that shared an
identical V3 sequence (including 11S and 25E) with R5 clones. In this
case, CXCR4 use is determined entirely by sequence changes outside
of the V3 region. In subject 4, all eight clones that were evaluated
displayed dual-X tropism and shared similar V3 sequences, yet only
two clones contained the 11R substitution, whereas the remaining six
clones had 11S. We conclude from these ﬁndings that the 11R-
containing variants frequently contribute to efﬁcient CXCR4 use, but
this substitution is not a requisite determinant.
CXCR4 utilization by env sequences containing 25K or 25R substitutions
in V3 is context dependent
Evaluation of the contribution of basic amino acid substitutions at
position 25 to CXCR4 use was similarly conducted by characterizing
the tropism and V3 sequences of multiple env molecular clones
derived from ﬁve patient virus populations (env subtype B=4, C=1)ons at position 25 in V3.
No. of
AA
changesd
Coreceptor
tropisme
Infectivity (RLU)f
CXCR4+ cells CCR5+ cells
R5 62 383,806
DIRQAHC 0 R5 70 1,796,486
....... 1 R5 92 1,559,819
....... 1 R5 79 1,799,031
....... 1 R5 51 552,861
R5 66 148,806
DIRQAYC 0 R5 54 359,517
....... 2 R5 81 149,570
DM 709,584 661,721
DIRQAHC 0 R5 182 298,585
...E... 3 R5 172 128,256
....... 3 Dual-X 630,016 660,567
DM 2701 27,905
NIRQAHC 0 R5 79 559,320
KVK.... 10 X4 497,805 133
DM 62,552 392,667
DIRQAYC 0 R5 85 503,528
G...... 1 R5 63 1,029,078
.....H. 11 Dual-X 1,487,002 1,754,137
.....H. 13 X4 356,894 122
N....H. 15 X4 137,117 86
ther.
ashes indicate gaps to accommodate insertions. Positions 11, 25, and 6–8 (for PNGS) are
es in the same sample is indicated.
ed as dual-X and dual-R based on efﬁcient or inefﬁcient utilization of CXCR4, as deﬁned
y. RLU b200 on CCR5+ or CXCR4+ cells was considered background luciferase activity in
rage RLU.
Table 4
env clonal analysis of three patient virus populations containing mixed amino acid substitutions that disrupt a PNGS at positions 6–8 in V3.
Subject
(subtype)
Virusesa No. of
PNGS at
positions
6–8b
V3 amino acid sequencesc No. of
AA
changesd
Coreceptor
tropisme
Infectivity (RLU)f
CXCR4+ cells CCR5+ cells
10(B) Population 0/1 R5 54 18,687
Clone (n=8) 0 CTRPNTNTRKSITIGPGRAFYATGGIIGDIRQAHC 0 R5 74 335,296
Clone (n=1) 0 .....A............................. 1 R5 100 201,829
Clone (n=1) 1 .....N......HM..........K.......... 4 R5 107 520,939
11(B) Population 0/1 R5 163 59,137
Clone (n=5) 1 CTRPNNNTRKSITIGPGRAFYTTGEIIGNIRQAQC 0 R5 66 580,001
Clone (n=1) 1 .......S........................... 1 R5 101 715,276
Clone (n=2) 0 .......R.................V..D....Y. 4 R5 72 34,875
Clone (n=1) 0 ......DR.............A..KV..D....Y. 7 R5 74 1563
Clone (n=1) 0 .......R.............A..KV..D....Y. 6 R5 55 6777
12(A) Population 0/1 DM 20,924 216,146
Clone (n=5) 1 CIRPNNNTRTSIHIGPGRAFYARGDITGDIRKAYC 0 R5 101 950,986
Clone (n=2) 1 ................................... 0 Dual-R 898 1,148,595
Clone (n=1) 0 .......A........................... 1 R5 118 703,962
Clone (n=2) 0 .R...IHKM.GVR.......F..QAM......... 12 Dual-X 569,619 1785
a Clones with identical V3 sequences and the same coreceptor tropism are grouped together. One R5 clone from subject 11 (indicated in bold) was chosen for site directed
mutagenesis.
b The absence of the potential N-linked glycosylation site (PNGS) at positions 6–8 in V3 are shown in boldface.
c For V3 amino acid sequences, dots represent amino acids identical to the ﬁrst sequence. Positions 11, 25, and 6–8 (for PNGS) are underlined.
d The number of amino acids that differ from the most prevalent V3 sequence of R5 clones in the same sample is indicated.
e Coreceptor tropism was determined by the Troﬁle assay. Dual clones were further classiﬁed as dual-X and dual-R based on efﬁcient or inefﬁcient utilization of CXCR4, as
previously described (Huang et al., 2007).
f Infectivity wasmeasured as luciferase activity (relative light units, RLU) in the Troﬁle assay. RLU b200 on CCR5+ or CXCR4+ cells was considered background luciferase activity in
this study. Infectivity of multiple clones with the same V3 sequence is expressed as the average RLU.
312 W. Huang et al. / Virology 409 (2011) 308–318that exhibitedmixed amino acid sequences at position 25 (Table 3). In
subjects 5–9, virus subpopulations containing either 25K or 25R co-
existed with subpopulations containing 25E, 25D, or 25 G. In subjects
5 and 6, all of the clones evaluated shared similar V3 sequences and
did not utilize CXCR4, i.e. were R5, irrespective of the presence or
absence of a basic amino acid substitution (K or R) at position 25.
Conversely, in subjects 7, 8, and 9, all clones containing 25K or 25R
were able to use CXCR4, i.e., were dual or X4 (105–106 RLU). Notably,
the V3 sequences of these variants also contained numerous
additional substitutions relative to the V3 sequence of the most
predominant R5 variants.1 2 3 4 5 6
PPosition 11
Subject
R
R
R R
R
R
S
S
S
S GG
S
S
S VDK
E G
RN
o.
 o
f V
3 
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15
Fig. 1. The number of V3 amino acid differences among env clones from each of 12 subjects.
sequence of R5 clones in the same sample (except for subject 4). Subject 4 contained only
between clones with or without 11R is shown. R5 and dual-R (efﬁcient CXCR4 utilization) clo
The amino acid substitution or number of PNGS is shown within each symbol.CXCR4 utilization by env sequences lacking a PNGS at positions 6–8 in
V3 is context dependent
We isolated and characterized the tropism and V3 sequences of
multiple env molecular clones derived from three patient virus
populations (env subtype B=2, A=1) that exhibited mixed PNGS
at V3 positions 6–8 (Table 4). In subjects 10 and 11, none of the clones
evaluated utilized CXCR4, i.e., were R5, irrespective of the presence or
absence of a PNGS at positions 6–8, and in the case of subject 11, the
presence of 25K as well. Conversely, in subject 12, dual-X variants
lacking the PNGS utilized CXCR4 efﬁciently (N105 RLU) when they7 8 9 10 11 12
Position 6-8
(No. of PNGS)
osition 25
E K
E D
K
R
R
R
E
E
0
0
1
0
0
0
0
0
1
1 1 1
Each symbol represents a unique V3 sequences that differs from the most prevalent V3
dual-X clones (efﬁcient CXCR4 utilization) and the number of amino acid differences
nes are indicated by open squares, dual-X and X4 clones are indicated by ﬁlled squares.
313W. Huang et al. / Virology 409 (2011) 308–318also contained additional substitutions relative to the V3 sequences of
the most predominant R5 variants. Based on the clonal analyses
presented in Tables 3 and 4, we conclude that the contribution of basic
amino acid substitutions at position 25, or the absence of PNGS at
positions 6–8, to CXCR4 use is highly dependent on the context of the
env sequence, in particular, the V3 region.An accumulation of multiple amino acid changes in V3 is required for
efﬁcient utilization of CXCR4
It should be noted that env variants that are capable of utilizing
CXCR4, i.e., dual-X and X4, were characterized by multiple amino acid
substitutions in V3 relative to R5 variants within the same virus
population. The number of amino acid differences among env clones
in each virus population is summarized in Fig. 1. Furthermore, the
association between the presence of basic amino acid substitutions at
positions 11 and 25 or the loss of a PNGS at positions 6–8, and CXCR4
use appears to be reliant on the presence of additional mutations in V3
(Fig. 1 and Tables 2–4). For example, although all 11R variants were
dual-X, they also contained 5–8 additional amino acid substitutions in
V3 relative to R5 clones from the same virus population (Table 2,
subjects 1–3). Similarly, CXCR4-using variants containing 25K or 25R
substitutions, or lacking the PNGS at positions 6–8, also contained 3–
15 different amino acids in V3 compared to R5 clones within the same
virus population (Table 3, subjects 7, 8, and 9, and Table 4, subject 12).
Overall, the number of different V3 amino acid substitutions in env
sequences containing 11R or 25K/R or lacking a PNGS at positions 6–
8 was noticeably higher for X4 and dual-X variants (mean=9,
range=3-15) compared to R5 and dual-R variants within the same
virus population (mean=1, range=0–5). We interpret these data as
evidence that the evolution of CXCR4 use either by the acquisition of
basic amino acid substitutions at position 11 or 25, or the loss of aTable 5
Coreceptor utilization of site-directed mutants using three R5 and two dual env backbones
Source of env backbonea V3 mutationsb Coreceptor
tropism
JRCSF (R5) S11, E25, PNGS(+) R5
S11K Dual
S11R Dual
E25K Dual
E25R Dual
PNGS(−) Dual
BaL (R5) S11, E25, PNGS(+) R5
S11K R5
S11R Dual
E25K Dual
E25R Dual
PNGS(−) Dual
c11.2 (R5) (subject 11) S11, E25, PNGS(+) R5
S11K R5
S11R R5
E25K R5
E25R R5
PNGS(−) R5
c2.41 (Dual) (subject 2) R11, Q25, PNGS(+) Dual
R11S Dual
c3.14 (Dual) (subject 3) R11, E25, PNGS(+) Dual
R11S Dual
a Five distinct env sequences were used to generate site-directed mutants: parental JRCSF
c2.41 and c3.14 (isolated from subjects 2 and 3) env sequences are dual.
b The listed substitutions were introduced into the V3 region of three R5 env sequences (JR
of PNGS at positions 6–8 is indicated as + or −. PNGS(−) mutants of R5 env sequences we
c Infectivity was measured as luciferase activity (relative light units, RLU) in the Troﬁle ass
in this study.
d CCR5-mediated entry of each mutant env sequence is represented as a percentage of thPNGS at positions 6–8, also involves the accumulation of additional V3
amino acid changes that may contribute to either efﬁcient CXCR4 use
or improvements in env infectivity.Introduction of 11K/R, 25K/R, or N6Q mutations into the V3 region of R5
env sequences clariﬁes mutational pathways and genetic barriers to
CXCR4 use
We used site-directed mutagenesis to engineer a panel of isogenic
viruses that could be used to clearly establish the impact of basic
amino acid substitutions at positions 11 and 25 of V3, or the loss of a
PNGS site at positions 6–8, on coreceptor utilization and env
infectivity (Table 5). Single V3 mutations (11K, 11R, 25K, 25R, N6Q)
were introduced into the env sequences of three R5 viruses: the well-
characterized JRCSF and BaL strains andmolecular clone c11.2 isolated
from the virus population of subject 11. Clone c11.2 (S11, E25, N6)
was chosen as the third R5 env backbone sequence for these studies
because all variants analyzed from the parental patient virus
population were R5, irrespective of the presence of a basic amino
acid substitution at position 25 (K) and/or the absence of a PNGS at
positions 6–8 (Table 4).
The introduction of the 11K substitution into the three R5 env
sequences conferred detectable levels of CXCR4-mediated entry to
JRCSF env (N103 RLU) but not BaL and c11.2 envs (Table 5). Notably,
the introduction of 11K was also associated with reductions in env-
mediated infectivity on CCR5+ cells (23%, 5%, and 2% relative to the
parental JRCSF, BaL, and c11.2 parental envs, respectively). Similarly,
the introduction of the 11R substitution conferred CXCR4-mediated
entry to the JRCSF and BaL envs (N104 RLU) but not to the clone c11.2
env. Again, the introduction of 11R was accompanied by reductions in
infectivity on CCR5+ cells (49%, 31%, and 22% relative to the JRCSF,
BaL, and c11.2 parental clones, respectively). Taken together, these.
Infectivity (RLU)c
CXCR4+ cells CCR5+ cells % R5 RLU relative to
parental envd
193 1,321,140 100
1929 299,175 23
35,195 655,246 49
22,303 829,696 63
40,693 816,309 62
47,206 3,234,479 245
90 2,420,047 100
191 123,724 5
11,597 757,409 31
14,063 2,795,704 116
37,674 2,079,533 86
1899 1,542,274 64
60 308,852 100
87 6157 2
78 67,408 22
77 152,441 49
70 117,422 38
78 62,047 20
632,384 400,342 100
586,581 600,991 150
790,017 342,895 100
525,764 317,581 93
, BaL, and clone c11.2 (isolated from subject 11) env sequences are R5; parental clones
CSF, BaL, and c11.2) and two dual env sequences (c2.41, c3.14). The presence or absence
re engineered by the introduction of N6Q substitutions.
ay. RLU b200 on CCR5+ or CXCR4+ cells was considered background luciferase activity
e parental env sequence.
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determinants of CXCR4 use, but when introduced as single mutations,
their contributions are partially obscured by impairments in env
infectivity in the absence of compensatory mutations.
The introduction of the 25K or 25R substitutions conferred CXCR4-
mediated entry to JRCSF and BaL (N104 RLU) but not clone c11.2. In
contrast to the 11K and 11R substitutions, the 25K and the 25R
substitutions did not severely impair infectivity on CCR5 cells,
suggesting that these two substitutions do not dramatically reduce
overall env infectivity (Table 5). Thus, the ability of the 25K and 25R
substitutions to confer CXCR4 use to some, but not all, R5 env
sequences was more apparent than the 11K and 11R substitutions.
Disruption of the PNGS in the V3 regions of the three R5 env
sequences was accomplished by the introduction of an N6Qmutation.
Loss of the PNGS conferred detectable levels of CXCR4 use to JRCSF
(N104 RLU) and BaL (N103 RLU). However, infection of CXCR4+ cells
was not observed with the c11.2 env containing the N6Q mutation
(Table 5). The effects of the loss of the PNGS on CCR5-mediated entry
varied widely, ranging from 20% to 245% for the c11.2 and JR-CSF
mutants, respectively. The reduction in CCR5 cell infectivity of theFig. 2. Structural modeling of the V3 regions of paired R5 and dual env clones from four
depicted (positive charges in blue, negative charges in red). Gains in positive charge a
sequences are provided below each modeled structure, and basic amino acids are highl
vs. 25K), and subject 9 (E25 vs. 25R).c11.2 mutant implies that compensatory mutations may be required
to obtain efﬁcient CXCR4 use by this R5 env sequence.Reversion of R to S at position 11 does not reduce the ability of patient
viruses to use CXCR4
To further test the role of V3 substitutions on CXCR4 use by
patient virus isolates, we used site-directed mutagenesis to revert
R substitutions to S substitutions at position 11. The infectivity of
two dual clones (c2.41 and c3.14) containing 11R from subjects 2
and 3, and their respective mutants with a single R11S change are
shown in Table 5. Interestingly, the two mutants with the R11S
substitution retained the dual-tropic phenotype, and their ability
to use CXCR4 and CCR5 for entry was not reduced relative to the
parental clones. These data, together with experiments described
above, conﬁrm that backbone env sequences collectively contrib-
ute to CXCR4 use and can strongly inﬂuence the effects of speciﬁc
V3 determinants of CXCR4 use, such as 11R, 25K/R, and loss of a
PNGS.patient virus populations. Patterns of electrostatic charge across the V3 region are
t positions 11 and 25 are highlighted by * and ^, respectively. The V3 amino acid
ighted in light blue. Subject 2 (G11 vs. 11R), subject 3 (S11 vs. 11R), subject 7 (E25
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To further examine the inﬂuence of V3 amino acid substitutions on
CXCR4 use, we modeled the structure of the V3 loops of paired R5 and
dual clones from two subjects with 11R variants (G11R for subject 2
and S11R for subject 3) and two subjects with 25K/R variants (E25K
for subject 7 and E25R for subject 9) (Fig. 2). Compared to R5 clones,
each paired dual clone exhibited a large gain in positive electrostatic
charge. This is in agreement with previous reports describing higher
net charges in the V3 regions of CXCR4-using viruses (De Jong et al.,
1992; Fouchier et al., 1992). However, our modeling indicated that a
single basic amino acid substitution (R or K) at position 11 or 25 alone
was not sufﬁcient to produce the net change in positive charge
observed in the paired R5 and dual clones (data not shown). This
result suggests that the other V3 amino acids substitutions observed
in dual clones contribute to the observed differences in electrostatic
charge and are consistent with our genotypic and phenotypic
characterizations described above. Furthermore, the amino acid side
chains of S or G at position 11 are considerably smaller than the
corresponding R and K side chains. Consequently, the S and G side
chains are free to face and perhaps form stabilizing hydrogen bonds
with the opposing V3 stem, as observed in our models. In contrast,
steric constraints imposed an outward positioning of the R and K side
chains relative to the opposing V3 stem. At position 25, the side chains
of E, R, or K are more similar in size, and as such, all are sterically
restricted away from the opposing V3 stem. The disparate positioning
of amino acid side chains at position 11 and the consistent positioning
of amino acid side chains at position 25 in R5 and dual clones may
explain the impaired env infectivity that is observed for site-directed
mutants containing 11R/K mutations but not 25R/K mutations.
Discussion
In this study, we have investigated the effect of different V3
mutational pathways on CXCR4 mediated entry, including the
acquisition of positively charged amino acids or the loss of PNGS.
Speciﬁcally, we characterized coreceptor usage among patient viruses
that contained K or R substitutions at position 11 or 25 or that lacked a
PNGS at amino acid positions 6–8. We found that all patient viruses
with a basic amino acid substitution at position 11 contained R
substitutions and were able to utilize CXCR4. Viruses with 11K
substitutions were not observed in the group of 200 patient viruses
characterized in this study, or a larger survey of N1000 patient virus
sequences. Conversely, CXCR4-mediated entry was variable among
patient viruses containing K or R substitutions at position 25, or
lacking a PNGS at positions 6–8, including a subset of viruses that
exhibited an R5 phenotype. Analysis of individual env clones
containing these V3 changes conﬁrmed our observations within
virus populations. All env clones containing 11R substitutions utilized
CXCR4 for entry, whereas only a subset of clones that contained either
a 25K or 25R substitution or that lacked a PNGS site at positions 6–
8 exhibited CXCR4-mediated entry. Current V3 sequence based
tropism prediction methods (PSSM and 11/25 rule) are limited in
their ability to accurately predict coreceptor use of viruses that lack K
or R at position 11 (Table 1).
Our initial observations indicate that the presence of a basic amino
acid at position 11 of V3 might be a stronger determinant of CXCR4
use than a basic amino acid at position 25 or the absence of a PNGS at
positions 6–8. To substantiate this hypothesis, we used site-directed
mutagenesis to either introduce a basic amino acid substitutions at
position 11 or 25 or remove the PNGS at positions 6–8 in three distinct
R5 env sequences. We found that addition of either the 11K or 11R
substitution alone was sufﬁcient to confer CXCR4 use for 2/3 R5 env
sequences, but that themagnitude of this affect was partially obscured
by impairments in env infectivity, as noted by reductions in CCR5
mediated entry (most notably for the 11K substitution). The additionof 25K or 25R substitutions or disruption of the PNGSwas also capable
of conferring CXCR4 use; however, they were not consistently
accompanied by reductions in CCR5-mediated infectivity. These
results illustrate that the inﬂuence of individual V3 substitutions on
CXCR4 use is dependent on env sequence context.
Across three distinct R5 env backbones, larger reductions in env
infectivity were consistently observed with the 11K versus the 11R
substitution. We speculate that 11K substitutions may be more
incompatible with CCR5 utilization than 11R substitutions and
consequently subject to more stringent negative selective pressure
in vivo. Consistent with the observations in this study, a survey of 506
V3 sequences obtained from the Los Alamos National Laboratory
database indicates that serine (S, 90.3%) and glycine (G, 7.5%) are the
most prevalent substitutions at position 11 for R5 viruses. Examina-
tion of codons reveals a preferential selection for R over K at position
11: a transition from either S or G to R requires one base change while
transition to K requires two base changes. This genetic disadvantage
coupled with reductions in infectivity likely account for an extremely
low frequency of 11K substitutions found in patient isolates.
Overall increases in V3 sequence heterogeneity among CXCR4-
using virus populations have also been reported (Low et al., 2008;
Troyer et al., 2005). In our study, clonal analysis of the four patient
virus populations containing 11R substitutions revealed that, in three
cases (subjects 1, 2, and 3), all clones bearing 11R substitutions also
contained additional V3 amino acid substitutions (N=5–8) relative to
R5 clones that co-existed within the same virus population lacking
11R substitutions. In the remaining case (subject 4), both 11R and 11S
clones utilized CXCR4 and shared similar V3 sequences, suggesting
that 11R, per se, was not (or was no longer) the primary genetic
determinant of CXCR4-mediated entry. Furthermore, reversion of R to
S at position 11 by site-directed mutagenesis in dual env clones from
subjects 2 and 3 did not alter CXCR4 utilization relative to the parental
env clones. Based on the combined results of our database survey, site-
directedmutagenesis experiments, and clonal analyses of 11R viruses,
we invoke the following model that describes potential mutational
pathways that lead to efﬁcient CXCR4 use by 11R/K viruses: either
11R/K substitutions occur early, but require compensatory substitu-
tions in V3 that restore obligate losses in env infectivity, or 11R/K
substitutions occur late andmust be preceded by V3 substitutions that
provide more accommodating env contexts for 11R/K substitutions.
This model is consistent with a strong association between 11R/K
substitutions and efﬁcient CXCR4 use.
Similar to 11R viruses, CXCR4-using env clones that contained 25K
or 25R substitutions, or lacked a PNGS at positions 6–8, also contained
additional V3 amino acid substitutions (N=3–15), relative to R5 env
clones that co-existed within the same virus populations (subjects 7,
8, 9, and 12). However, unlike 11R/K substitutions, 25R/K substitu-
tions andmutations that result in loss of the PNGS at positions 6–8 are
not consistently associated with efﬁcient CXCR4 utilization or
reductions in env infectivity. Once again, based on the combined
results of our database survey, site-directed mutagenesis experi-
ments, and clonal analyses of 25K/R or PNGS(−) viruses, we invoke
the following model to describe potential mutational pathways that
lead to efﬁcient CXCR4 use by 25R/K viruses or viruses that lack a
PNGS at positions 6–8: 25R/K substitutions or loss of the PNGS may
occur early or late and are not associatedwith severe reductions in env
infectivity but require additional V3 substitutions that act coopera-
tively to confer efﬁcient CXCR4 utilization. This model is consistent
with a less stringent association between the presence of 25R/K
substitutions or the absence of a PNGS at positions 6–8 and efﬁcient
CXCR4 use.
The results of our V3 structural modeling exercises are consistent
with our experimental observations. The acquisition of efﬁcient
CXCR4 use is associated with notable increases in positive electro-
static charges along the V3 stem–loop structure relative to the V3
stem–loop structures of paired R5 viruses from the same virus
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charge are not acquired through single basic amino acid substitutions
at position 11 or 25 but rather require multiple amino acid
substitutions in the V3 sequence.
It is important to note that previous studies have demonstrated
that not all determinants of CXCR4 use reside within the V3 region.
Pastore et al., reported that substitutions in the V1/V2 regions of
gp120 restore losses in entry infectivity resulting from V3 mutations
and play an important role during coreceptor switching from CCR5 to
CXCR4 of viruses selected in vitro (Pastore et al., 2006). Previously, our
laboratory has reported that substitutions in gp41 of patient-derived
envs impacted CXCR4 utilization (Huang et al., 2008). Furthermore,
the replacement of V3 regions of X4 or dual env sequences with V3
regions of R5 env and vice versa, provides compelling evidence for the
existence of determinants of CXCR4 utilization outside of the V3
region (Huang et al., 2008). Consistent with these prior observations,
in this study we describe two env sequences from subject 3 that share
identical V3 sequences but differ notably in their ability to utilize
CXCR4 (R5 vs. dual-X). In addition, clones that inefﬁciently use CXCR4
(dual-R) and contain the same V3 sequence with R5 clones were also
identiﬁed.
The detailed characterization of 11R/K viruses that utilize CXCR4 in
this study provides a plausible explanation for the observation that
basic amino acid substitutions at position 11 but not 25, or losses in
PNGS at positions 6–8, are associated with more accurate predictions
of CXCR4 use. We postulate that 11R/K viruses likely escape from
CCR5 inhibitor treatment by their ability to utilize CXCR4 once
compensatory mutations accumulate to restore reductions in infec-
tivity. The phenotypic impact of V3 amino acid substitutions on
CXCR4 utilization by patient viruses presented in this study provides
further insight into the different mutational pathways and genetic
barriers for acquisition of CXCR4 use by clinical isolates.
Methods
Patient virus selection
To obtain viruses containing positively charged amino acids at
position 11 or 25 or lacking PNGS at positions 6–8 in the V3 region of
env, we determined the V3 nucleotide sequences of 200 patient
plasma-derived viruses (submitted for routine coreceptor tropism
[Troﬁle] testing), to obtain the 47 viruses described in this study.
Based on env sequences, 39 viruses were identiﬁed as subtype B and
8 samples as non-subtype B and recombinant (A=1, C=2, AE=1, A/
G=2, B/C=1, B/D=1). Thirty-ﬁve of 47 patient viruses contained
unambiguous V3 sequences (no mixtures) and a basic amino acid
substitution at either position 11 (N=7) or 25 (N=25) or that lacked
a PNGS at positions 6–8 (N=3). The remaining 12 patient viruses
containedmixed V3 amino acid sequences at position 11 (N=4) or 25
(N=5) or at positions 6–8 (N=3). For this subset of 12 viruses, we
also determined the V3 nucleotide sequences and coreceptor tropisms
for approximately 10 env clones per virus population. Since these 47
patient virus samples were submitted to Monogram for routine
coreceptor tropism testing, no clinical information or longitudinal
samples were available.
Site-directed mutagenesis
Single amino acid substitutions (S11K, S11R, E25K, E25R) were
introduced into the V3 regions of three R5 molecular env clones of
HIV-1: JRCSF and BaL (AIDS Research and Reference Reagent
Program), and clone c11.2 (from subject 11 in this study) using site-
directed mutagenesis (Sarkar and Sommer, 1990). The V3 PNGS was
removed from each of these three R5 env sequences by introducing an
N6Q mutation. In addition, 11R substitutions were replaced by 11S
substitutions in two dual env clones (c2.41, c3.14) derived fromsubjects 2 and 3. The complete gp160 nucleotide sequence of each
engineered env gene was determined to verify the presence of the
desired mutations and the absence of other mutations.
Coreceptor tropism determinations
The coreceptor tropisms of patient virus populations, molecular
env clones derived from patient virus populations, and env clones
containing site-directed mutations in V3 were determined using the
Troﬁle coreceptor tropism assay (Whitcomb et al., 2007). Brieﬂy, HIV-
1 env genes were ampliﬁed by RT–PCR and incorporated into env
expression vectors. HIV-1 pseudovirions were generated by co-
transfecting HEK-293 cells with env expression vectors and an HIV-
1 genomic vector containing a ﬁreﬂy luciferase reporter gene.
Coreceptor tropism was determined by measuring the ability of
pseudovirions to infect U87 target cells that express CD4 and either
CCR5 or CXCR4. In the Troﬁle assay, the production of luciferase
activity in CXCR4 and/or CCR5 target cells that exceed background
levels (~102 RLU in this study) and are inhibited by a CXCR4 or CCR5
inhibitor, respectively, is considered a demonstration of env-mediated
virus entry.
env V3 sequencing
V3 nucleotide sequences for patient virus populations and
molecular clones were determined using conventional dideoxy
chain terminator chemistry (ABI, Foster City, CA). V3 amino acid
sequences were deduced from nucleotide sequences. Predictions of
coreceptor tropism based on derived V3 amino acid sequences were
determined using two well-established algorithms; 11/25 rule and
PSSM (De Jong et al., 1992; Fouchier et al., 1992; Jensen et al., 2003).
env V3 structure modeling
The V3 sequences of paired R5 and dual clones from four subjects
(2, 3, 7, and 9), alongwith template structures 2QAD, 1U6U, and 2ESX,
were aligned by hand and modeled using MODELLER (Sali and
Blundell, 1993). Surface images with electrostatic forces were created
using Discovery Studio 2.5 software (http://accelrys.com/products/
discovery-studio/).
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